‘I Really Could Not Refuse’: Pharmascience CEO Arès Reflects On First Six Months
Canadian Generics Manufacturer Has Ambitions To Double Sales By End Of Decade
Executive Summary
Taking over from the son of the company’s founder at the beginning of 2023, Martin Arès, the CEO of Canadian generics manufacturer Pharmascience, talks to Generics Bulletin about investment, international expansion and biosimilars.
You may also be interested in...
Fresenius And Aurobindo Among Fresh Velcade Challengers In US
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’
Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).
Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim
Coherus BioSciences says that it will work closely with the US Food and Drug Administration and the unnamed third-party filler to obtain approval for its proposed version of Neulasta Onpro on-body injector “as quickly as possible.”